Wang WL, et al. (2015) Slug is temporally regulated by cyclin E in cell cycle and controls genome stability. Oncogene 34, 1116-25 24662826

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T160-p - CDK2 (human) ▲

Modsite: GVPVRtytHEVVtLW SwissProt Entrez-Gene Orthologous residues CDK2 (human): T160‑p, CDK2 iso2 (human): T160‑p, CDK2 (mouse): T160‑p, CDK2 (rat): T160‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer, lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma Relevant cell lines - cell types - tissues:  A549 (pulmonary), CL1-5 (pulmonary), HOP62 (pulmonary), U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Downstream Regulation Effect of modification (process):  cell cycle regulation

S54-p - Snail2 (human) ▲

Modsite: ILSSGAYsPITVWTT SwissProt Entrez-Gene Orthologous residues Snail2 (human): S54‑p, Snail2 (mouse): S54‑p, Snail2 (rat): S54‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  bone cancer, lung cancer Relevant cell lines - cell types - tissues:  CL1-5 (pulmonary), U2OS (bone cell) Cellular systems studied:  cell lines Enzymes shown to modify site in vitro:  Type Enzyme KINASE CDK2 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CDK2 (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, co-immunoprecipitation, transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes thymidine increase CHEMBL267048 decrease siRNA decrease siRNA for Cdk2 decreases phosphorylation Downstream Regulation Effect of modification (function):  protein degradation, ubiquitination Effect of modification (process):  cell cycle regulation

S104-p - Snail2 (human) ▲

Modsite: KDHsGSEsPISDEEE SwissProt Entrez-Gene Orthologous residues Snail2 (human): S104‑p, Snail2 (mouse): S105‑p, Snail2 (rat): S104‑p Characterization Methods used to characterize site in vivo:  [32P] ATP in vitro, mass spectrometry (in vitro), mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  bone cancer, lung cancer Relevant cell lines - cell types - tissues:  CL1-5 (pulmonary), U2OS (bone cell) Cellular systems studied:  cell lines Enzymes shown to modify site in vitro:  Type Enzyme KINASE CDK2 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CDK2 (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, co-immunoprecipitation, transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes CHEMBL267048 decrease siRNA decrease siRNA for Cdk2 decreases phosphorylation Downstream Regulation Effect of modification (function):  protein degradation, ubiquitination Effect of modification (process):  cell cycle regulation